![Ramon Mohanlal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ramon Mohanlal
Direktor/Vorstandsmitglied bei
Seed Therapeutics, Inc.
Profil
Ramon W.
Mohanlal is currently a Director at Seed Therapeutics, Inc. Prior to his current position, he served as Director, Chief Medical Officer, and Executive VP-R&D at BeyondSpring, Inc. from 2015 to 2023.
Ramon also held positions as Chief Medical Officer at Vertex Pharmaceuticals, Inc., Clinical Head-Established Oncology Products at Novartis AG, and Chief Executive & Medical Officer at BioPremiere, Inc. He was also a Principal at Glaxo Wellcome Plc and Pharmacia Corp.
Ramon holds a doctorate from the University of Leiden and an MBA from American InterContinental University System, Inc.
Aktive Positionen von Ramon Mohanlal
| Unternehmen | Position | Beginn |
|---|---|---|
Seed Therapeutics, Inc.
 Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang. | Direktor/Vorstandsmitglied | 01.08.2020 |
Ehemalige bekannte Positionen von Ramon Mohanlal
| Unternehmen | Position | Ende |
|---|---|---|
| BEYONDSPRING INC. | Technik-/Wissenschafts-/F&E-Leiter | 16.02.2023 |
| NOVARTIS AG | Corporate Officer/Principal | 01.07.2015 |
BioPremiere, Inc.
 BioPremiere, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Vorstandsvorsitzender | 01.01.2009 |
| INTERLEUKIN GENETICS, INC | Technik-/Wissenschafts-/F&E-Leiter | 17.08.2007 |
Glaxo Wellcome Plc
 Glaxo Wellcome Plc Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets pharmaceuticals | Corporate Officer/Principal | - |
Ausbildung von Ramon Mohanlal
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
51
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Glaxo Wellcome Plc
Glaxo Wellcome Plc Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets pharmaceuticals | Health Technology |
Interleukin Genetics, Inc.
 Interleukin Genetics, Inc. Pharmaceuticals: MajorHealth Technology Develops personalized health products | Health Technology |
American InterContinental University System, Inc.
 American InterContinental University System, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Health Technology |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioPremiere, Inc.
BioPremiere, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
BeyondSpring, Inc.
 BeyondSpring, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cancer therapies | Health Technology |
Seed Therapeutics, Inc.
Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang. | Commercial Services |
Wählen Sie MarketScreener 
